EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Tumor Heterogeneity and the Immune Response in Non-Small Cell Lung Cancer: Emerging Insights and Implications for Immunotherapy

Michael S Oh iD, Jensen Abascal iD, Austin K Rennels iD, Ramin Salehi-Rad, Steven M Dubinett, Bin Liu iD

Cancers · 19.03.2025 · 17 (6) · 1027

DOI: 10.3390/cancers17061027 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 19.03.2025. Verfasst von Michael S Oh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 212 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NCI NIH HHS, Tobacco-Related Disease Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistance to immune checkpoint inhibitors (ICIs) represents a major challenge for the effective treatment of non-small cell lung cancer (NSCLC). Tumor heterogeneity has been identified as an important mechanism of treatment resistance in cancer and has been increasingly implicated in ICI resistance. The diversity and clonality of tumor neoantigens, which represent the target epitopes for tumor-specific immune cells, have been shown to impact the efficacy of immunotherapy. Advances in genomic techniques have further enhanced our understanding of clonal landscapes within NSCLC and their evolution in response to therapy. In this review, we examine the role of tumor heterogeneity during immune surveillance in NSCLC and highlight its spatial and temporal evolution as revealed by modern technologies. We explore additional sources of heterogeneity, including epigenetic and metabolic factors, that have come under greater scrutiny as potential mediators of the immune response. We finally discuss the implications of tumor heterogeneity on the efficacy of ICIs and highlight potential strategies for overcoming therapeutic resistance.

Schlagwörter

Stichwörter der Autor:innen

heterogeneityimmunotherapynon-small cell lung cancertumor evolution

Autor:innen und Institutionen

  • Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
  • Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA.
  • Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA.

ORCID-Profile: Michael S Oh, Jensen Abascal, Austin K Rennels, Bin Liu

Förderung

  • BLRD VA
  • NCI NIH HHS
  • Tobacco-Related Disease Research Program
  • Department of Veterans Affairs Career Development Award
  • Department of Veterans Affairs Merit Review Research funds
  • Department of Veterans Affairs Lung Precision Oncology Program

Zitieren

APA

Oh, M. S., Abascal, J., Rennels, A. K., Salehi-Rad, R., Dubinett, S. M., & Liu, B. (2025). Tumor Heterogeneity and the Immune Response in Non-Small Cell Lung Cancer: Emerging Insights and Implications for Immunotherapy. Cancers, 17(6), 1027. https://doi.org/10.3390/cancers17061027

Vancouver

Oh MS, Abascal J, Rennels AK, Salehi-Rad R, Dubinett SM, Liu B. Tumor Heterogeneity and the Immune Response in Non-Small Cell Lung Cancer: Emerging Insights and Implications for Immunotherapy. Cancers. 2025;17(6):1027. doi:10.3390/cancers17061027

BibTeX
@article{Oh2025,
  author = {Oh, Michael S and Abascal, Jensen and Rennels, Austin K and Salehi-Rad, Ramin and Dubinett, Steven M and Liu, Bin},
  title = {Tumor Heterogeneity and the Immune Response in Non-Small Cell Lung Cancer: Emerging Insights and Implications for Immunotherapy},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {6},
  pages = {1027},
  doi = {10.3390/cancers17061027}
}
Kostenlos starten →